Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition

Circulation

Volumn 107, Issue 23, 2003, Pages 2949-2954

  Tank, Jens ^a   Schroeder, Christoph ^a   Diedrich, Andre ^c   Szczech, Elke ^a   Haertter, Sebastian ^b   Sharma, Arya M ^a   Luft, Friedrich C ^a   Jordan, Jens ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Antidepressive agents; Baroreflex; Catecholamines; Nervous system, autonomic; Receptors, adrenergic, alpha

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; CATECHOLAMINE; NITROPRUSSIDE SODIUM; NORADRENALIN; NORADRENALIN TRANSPORTER; PHENYLEPHRINE; PLACEBO; REBOXETINE;

ADRENERGIC SYSTEM; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; HEART RATE; HUMAN; HUMAN EXPERIMENT; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; SYMPATHETIC NERVE; VASOMOTOR REFLEX;

ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ADULT; BAROREFLEX; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MORPHOLINES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; REFERENCE VALUES; SYMPATHETIC NERVOUS SYSTEM; SYMPORTERS; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; VASOMOTOR SYSTEM;

EID: 0037973672     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000072786.99163.FE     Document Type: Article

References (27)

1. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial, STORM Study Group Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119-2125.
2. Rumantir MS, Kaye DM, Jennings GL, et al. Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension. Hypertension. 2000;36:824-829.
3. Shannon JR, Flattem N, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine transporter deficiency. N Engl J Med. 2000;342:541-549.
4. Schroeder C, Tank J, Boschmann M, et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 2002;105:347-353.
5. Kahan T, Hjemdahl P, Dahlof C. Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle. Acta Physiol Scand. 1984;122:571-582.
6. , Esler MD, Wallin G, Dorward PK, et al. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol. 1991;260:R817-R823.
7. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation. 2002;106:2459-2465.
8. Jordan J, Tank J, Shannon JR, et al. Baroreflex buffering and susceptibility to vasoactive drugs. Circulation. 2002;105:1459-1464.
9. Tank J, Diedrich A, Schroeder C, et al. Limited effect of systemic β-blockade on sympathetic outflow. Hypertension. 2001;38:1377-1381.
10. Boschmann M, Schroeder C, Christensen NJ, et al. Norepinephrine transporter function and autonomic control of metabolism. J Clin Endocrinol Metab. 2002;87:5130-5137.
11. Tank J, Baevski RM, Fender A, et al. Reference values of indices of spontaneous baroreceptor reflex sensitivity. Am J Hypertens. 2000;13:268-275.
12. Tank J, Jordan J, Diedrich A, et al. Genetic influences on baroreflex function in normal twins. Hypertension. 2001;37:907-910.
13. Wong EH, Sonders MS, Amara SG, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 2000;47:818-829.
14. Goldstein DS, Eisenhofer G, Stull R, et al. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81:213-220.
15. Furlan R, Porta A, Costa F, et al. Oscillatory patterns in sympathetic neural discharge and cardiovascular variables during orthostatic stimulus. Circulation. 2000;101:886-892.
16. Eisenhofer G, Saigusa T, Esler MD, et al. Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. Am J Physiol. 1991;260:R824-R832.
17. Montano N, Ruscone TG, Porta A, et al. Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt [see comments]. Circulation. 1994;90:1826-1831.
18. Malliani A, Pagani M, Lombardi F, et al. Cardiovascular neural regulation explored in the frequency domain. Circulation. 1991;84:482-492.
19. Furlan R, Jacob G, Snell M, et al. Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation. 1998;98:2154-2159.
20. Jordan J, Shannon JR, Black B, et al. Malignant vagotonia due to selective baroreflex failure. Hypertension. 1997;30:1072-1077.
21. 2-adrenoreceptor responsiveness in autonomic dysfunction. J Am Coll Cardiol. 1984;3:850-856.
22. Jordan J, Shannon JR, Biaggioni I, et al. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105:116-124.
23. Mohring J, Glanzer K, Maciel JJ, et al. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol. 1980;2:367-376.
24. Jordan J, Shannon JR, Pohar B, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol. 1999;10:35-42.
25. Page IH, McCubbin JW. Buffer reflexes, tolerance to ganglioplegics and their relationship to enhanced pressor responsiveness. Am J Physiol. 1959;197:217-222.
26. Haas E, Goldblatt H. Effects of various ganglionic blocking agents on blood pressure and on activity of pressor agents. J Physiol. 1960;198:1023-1028.
27. N-cholinergic blockade in dissecting the components of cardiovascular regulation. Hypertension. 1998;32:101-107.